Skip to main content

Table 1 Patient characteristics

From: Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study

  All sUA < 6.0 mg/dl sUA ≥ 6.0 mg/dl p value
Patients, n (%) 178 78 100  
Male, n (%) 121 (68%) 42 (54%) 79 (79%) < 0.001
Age, years (range) 65 (15–89) 66 (17–89) 64 (15–88) n.s.
Baseline systolic BP, mmHg (range) 130 (85–180) 129 (85–170) 130 (96–180) n.s.
Baseline diastolic BP, mmHg (range) 76 (45–110) 74 (50–110) 76 (45–106) n.s.
Primary diseases of CKD
 Diabetic nephropathy, n (%) 33 (19%) 9 (12%) 24 (24%) n.s.
 Chronic nephritis, n (%) 36 (20%) 19 (24%) 17 (17%) n.s.
 Nephrosclerosis, n (%) 34 (19%) 14 (18%) 20 (20%) n.s.
 Others, n (%) 75 (42%) 36 (46%) 39 (39%) n.s.
Complications
 Diabetes mellitus, n (%) 45 (25%) 17 (22%) 28 (28%) n.s.
 Hypertension, n (%) 137 (77%) 56 (72%) 81 (81%) n.s.
 Abnormal cholesterol levels, n (%) 94 (53%) 34 (44%) 60 (60%) n.s.
 Coronary artery disease, n (%) 12 (7%) 4 (5%) 8 (8%) n.s.
Estimated GFR at baseline, ml/min/1.73 m2 27.0 (7.3–101.7) 27.7 (7.3–78.9) 26.0 (9–101.7) n.s.
Urine protein levels at baseline, g/gCre 0.67 (0.00–17.7) 0.45 (0.00–7.2) 0.78 (0.00–17.7) n.s.
Serum uric acid at baseline, mg/dl 8.3 (3.9–12.6) 8.3 (3.9–10.7) 8.7 (5.2–12.6) 0.042
CKD stage
 G1–2, n (%) 13 (7%) 6 (8%) 7 (7%) n.s.
 G3, n (%) 62 (35%) 29 (37%) 33 (33%) n.s.
 G4–5, n (%) 103 (58%) 43 (55%) 60 (60%) n.s.
Antihyperuricemics before febuxostat
 None, n (%) 118 (66%) 58 (74%) 60 (60%) n.s.
 Allopurinol, n (%) 44 (25%) 14 (18%) 30 (30%) n.s
 Benzbromarone, n (%) 14 (8%) 6 (8%) 8 (8%) n.s.
 Allopurinol and benzbromarone, n (%) 2 (1%) 0 (0%) 2 (2%) n.s.
Febuxostat dose after 6 months
 10 mg/day, n (%) 103 (58%) 51 (66%) 52 (52%) n.s.
 20 mg/day, n (%) 61 (34%) 22 (28%) 40 (39%) n.s.
 40 mg/day, n (%) 14 (8%) 5 (6%) 9 (9%) n.s.
\